Disease · MONDO_0005004

clear cell adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. clear cell adenocarcinoma. Diseases, record MONDO_0005004. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005004

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: clear cell adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005004; Open Targets
Other names: Mesonephroid clear cell adenocarcinoma, Mesonephroid clear cell carcinoma, Mesonephroma, malignant, Mesonephroma, malignant (morphologic abnormality), Wolffian duct neoplasm, adenocarcinoma, clear cell, malignant, clear cell adenocarcinoma (morphologic abnormality), clear cell adenocarcinoma NOS (morphologic abnormality), clear cell carcinoma, conventional clear cell renal carcinoma, malignant Mesonephroma, mesonephroma NOS (morphologic abnormality), water-clear cell adenocarcinoma, water-clear cell adenocarcinoma (morphologic abnormality), water-clear cell carcinoma; Open Targets
Disease Ontology: DOID:4468; Disease Ontology
MeSH: D018262; MeSH
NCI Thesaurus: C3766; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 10 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AXITINIB	CHEMBL1289926	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENMD-2076	CHEMBL482968	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RISOVALISIB	CHEMBL4800252	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SINTILIMAB	CHEMBL4297829	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets81

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
AURKA	Aurora kinase A	1	Serine/threonine-protein kinase Aurora-A inhibitor	Phase 2	https://conductscience.org/library/genes/6790	Drugs and targets
AURKB	Aurora kinase B	1	Serine/threonine-protein kinase Aurora-B inhibitor	Phase 2	https://conductscience.org/library/genes/9212	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1/2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 1/2	https://conductscience.org/library/genes/56901	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
FGFR3	Fibroblast growth factor receptor 3	1	Fibroblast growth factor receptor 3 inhibitor	Phase 2	https://conductscience.org/library/genes/2261	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets

1 to 10 of 81

See all 81 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01914510	A Study of ENMD-2076 in Ovarian Clear Cell Cancers	Phase 2	40	2019-12-13	Ovarian Clear Cell Carcinoma	ENMD-2076	Open Targets' reading of its record	ClinicalTrials.gov
NCT06023862	A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)	Phase 2	198		Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell Carcinoma	BEVACIZUMAB, DOSTARLIMAB	Its record names the disease	ClinicalTrials.gov
NCT05043922	A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma	Phase 2	93		Ovarian Cancer, Recurrent Cancer	RISOVALISIB	Its record names the disease	ClinicalTrials.gov
NCT03405454	A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas	Phase 2	46		Ovarian Clear Cell Carcinoma	DURVALUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04735861	Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma	Phase 2	38		Ovarian Clear Cell Carcinoma	BEVACIZUMAB, SINTILIMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT06889649	SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC	Phase 2	30		Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic	AXITINIB, TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT03935256	Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer	Phase 2	24		Endometrial Cancer	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT06065462	Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100	Phase 1/2	21		Ovarian Clear Cell Carcinoma	DOSTARLIMAB, LB-100	Open Targets' reading of its record	ClinicalTrials.gov
NCT05759312	Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma	Phase 1/2	20		Ovarian Clear Cell Carcinoma	METFORMIN, ZIMBERELIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05941637	An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)				Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations	AXITINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
43008753	DERIVED	1	PubMed
40503038	DERIVED	1	PubMed
39710508	DERIVED	1	PubMed
39276785	DERIVED	1	PubMed
38932511	DERIVED	1	PubMed
35613822	DERIVED	1	PubMed
32591370	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005004

GET https://conductscience.org/api/diseases/v1/MONDO_0005004/targets?page=2

API reference For AI assistants